Back to News
Market Impact: 0.55
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Source: reuters.com
Healthcare & BiotechCompany FundamentalsCorporate Guidance & OutlookLegal & Litigation

Ultragenyx Pharmaceutical shares fell more than 40% in premarket after its late-stage trial for a neurodevelopmental disorder treatment failed, undermining a key growth bet. The setback is a major negative catalyst for the company’s clinical pipeline and near-term outlook. The magnitude of the drop suggests investors repriced the probability of success for future revenue streams.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.75
Ticker Sentiment
RARE-0.80
More News
- Broadcom CEO addresses Anthropic's slowdown push, says AI revenue targets haven't changed
- US repeals rules limiting greenhouse gas emissions by power plants
- Bank of America expects third-quarter investment banking fees to fall more than 10%; shares slide
- Samsung backs Nvidia AI chip rival in $230 million funding round as GPU alternatives boom
- What's next for oil refiners after an unprecedented run to all-time highs
- Anthropic walks tightrope to Nasdaq, pushing for a slowdown while pursuing $2 trillion valuation